期刊文献+

Ph(-)慢性骨髓增殖性疾病JAK2V617F检测技术及临床应用的进展 被引量:1

下载PDF
导出
摘要 2005年以来多个研究组报道了在Ph(-)慢性骨髓增殖性疾病患者的外周血和骨髓中存在JAK2V617F突变,所用的检测方法有DNA直接测序、序列特异性PCR、实时定量PCR与DNA溶链曲线分析、限制性片段长度多态性、焦磷酸测序,兹就这些方法的原理、敏感性以及临床应用进行综述。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2008年第11期1123-1125,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 江苏省科技厅社会发展项目(BS2003603) 江苏省医学重点人才基金资助项目(RC2007002) 南京市医学科技重点项目(ZKX06013)
  • 相关文献

参考文献19

  • 1Vardiman JW, Harris NL, Brunning RD. The World Health Organization ( WHO ) classification of the myeloid neoplasms [ J ]. Blood, 2002, 100(7) : 2292 -2302. 被引量:1
  • 2Baxter E J, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[ J]. Lancet, 2005, 365(9464): 1054-1061. 被引量:1
  • 3Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352(17) : 1779 - 1790. 被引量:1
  • 4Ingley E , Klinken SP. Cross-regulation of JAK and Src kinases[ J]. Growth Factors, 2006, 24 ( 1 ) : 89 - 95. 被引量:1
  • 5Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a routine bone marrow transplant model [ J ]. Blood, 2006, 107 (11) : 4274 -4281. 被引量:1
  • 6Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology[ J]. J Mol Diagn, 2006, 8(4) : 397 -411. 被引量:1
  • 7Izmailov A, Goloubentzev D, Jin C, et al. A general approach to the analysis of errors and failure modes in the base-calling function in automated fluorescent DNA sequencing [ J ]. Electrophoresis, 2002, 23 (16) : 2720 -2728. 被引量:1
  • 8Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [ J ]. N Engl J Med, 2007, 356(5) : 459 -468. 被引量:1
  • 9Butcher CM, Hahn U, To LB, et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients[ J ]. Leukemia, 2008, 22(4) : 870 -873. 被引量:1
  • 10Grunebach F, Bross-Bach U, Kanz L, et al. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera[J]. Leukemia, 2006, 20(12) : 2210 -2211. 被引量:1

二级参考文献6

  • 1Wolanskyj AP,Lasho TL,Schwager SM,et al.JAK2 mutation in essential thrombocythaemia:clinical associations and long-term prognostic relevance.Br J Haematol,2005,131:208-213. 被引量:1
  • 2Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet,2005,365:1054-1061. 被引量:1
  • 3Kralovics R,Passamonti F,Buser AS,et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med,2005,352:1779-1790. 被引量:1
  • 4Levine RL,Wadleigh M,Cool J,et al.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia,and myeloid metaplasia with myelofibrosis.Cancer Cell,2005,7:387-397. 被引量:1
  • 5Lee JW,Kim YG,Soung YH,et al.The JAK2 V617F mutation in de novo acute myelogenous leukemias.Oncogene,2006,25:1434-1436. 被引量:1
  • 6Levine RL,Loriaux M,Huntly BJ,et al.The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia,but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.Blood,2005,106:3377-3379. 被引量:1

共引文献21

同被引文献9

  • 1Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J]. Lancet, 2005, 365(9464): 1054-1061. 被引量:1
  • 2Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis[J]. Cancer Cell, 2005, 7(4): 387-397. 被引量:1
  • 3Wernig G, Mercher T, Okabe R,et al. Expression of Jak2V617F causes a polycythemia veralike disease with associated myelofibrosis in a murine bone marrow transplant model[J]. Blood, 2006, 107(11): 4274-4281. 被引量:1
  • 4Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J]. Leukemia, 2008, 22(1): 14-22. 被引量:1
  • 5Kutyavin IV, Afonina IA, Mills A, et al. 3′-Minor groove binderDNA probes increase sequence specificity at PCR extension temperatures[J]. Nucleic Acids Res, 2000, 28(2): 655-661. 被引量:1
  • 6Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms[J]. Blood, 2002, 100(7): 2292-2302. 被引量:1
  • 7Elizabeth CW, Katy H, Lorna WH, et al. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation[J].J Mol Diag, 2007, 9(1); 42-46. 被引量:1
  • 8Poodt J, Fijnheer R, Walsh IB, et al. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood[J]. Hematol Oncol, 2006, 24(4): 227-233. 被引量:1
  • 9阮国瑞,陈珊珊,李玲娣,刘艳荣,秦亚溱,李金兰,马曦,王峰蓉,江倩,江滨,刘开彦,黄晓军.TaqMan—MGB探针检测骨髓增殖性疾病患者JAK2V617F突变[J].中华医学杂志,2007,87(34):2401-2404. 被引量:2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部